Floatz logo

Sitravatinib

Metastatic Malignant Neoplasm

Mirati Therapeutics Inc.Small moleculePhase 2/3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
39/ 100
Competitive Position
95/ 100

Competitive context

276 Active assets in the Metastatic Malignant Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
I-Mab Biopharma US Limited
Phase 3BB
Irinotecan
Incyte Corporation
Phase 3BB
FILGRASTIM
Mayo Clinic
Phase 3BB
Cyclophosphamide
InSilico Medicine Hong Kong Limited
Phase 2/3BB
Pembrolizumab
InSilico Medicine Hong Kong Limited
Phase 2/3BB

View all 50 →

Same molecule, other indications

Sitravatinib is also rated in:

nonpapillary renal cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →
renal cell carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →